{"id":391159,"date":"2016-04-14T00:00:00","date_gmt":"2016-04-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acremd0004-2016-biopharma-type-2-diabetes-access-and-reimbursement-eu5-2016\/"},"modified":"2026-04-29T05:27:26","modified_gmt":"2026-04-29T05:27:26","slug":"acremd0004-2016-biopharma-type-2-diabetes-access-and-reimbursement-eu5-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acremd0004-2016-biopharma-type-2-diabetes-access-and-reimbursement-eu5-2016\/","title":{"rendered":"Type 2 Diabetes | Access and Reimbursement | EU5 | 2016"},"content":{"rendered":"<p>Type 2 diabetes (T2D) is a chronic metabolic disease affecting more than 28 million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At the core of T2D treatment is long-generic standard of care metformin (Merck KgaA\u2019s Glucophage, generics) as first-line therapy. However, T2D patients typically require therapeutic intensification, with drugs from several other classes, including DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists, and insulin analogues competing with generic alternatives for position as second- and third-line therapy status. These branded agents are competing in an increasingly cost-sensitive environment, and marketers need to provide clear evidence of clinical improvements and\/or cost benefits on well-defined clinical endpoints over well-entrenched, generically available standards-of-care to ensure favorable health technology assessment (HTA) and favorable pricing and reimbursement terms.<\/p>\n","protected":false},"template":"","class_list":["post-391159","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391159\/revisions"}],"predecessor-version":[{"id":394282,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391159\/revisions\/394282"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}